{
    "clinical_study": {
        "@rank": "48443", 
        "arm_group": [
            {
                "arm_group_label": "Lenalidomide plus Quinidine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lenalidomide plusTemsirolimus and Diphenhydramine", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To find out if the blood level of lenalidomide can be changed when  a drug that prevents\n      p-glycoprotein (a protein naturally present in the body that helps carry substances across\n      cell membranes that is found in many parts of the body like the intestines, liver, and\n      kidneys) from working (called a P-gp inhibitor) when taken together with lenalidomide.  The\n      study is also trying to find out if blood level of temsirolimus can be changed when a\n      subject takes lenalidomide together with temsirolimus."
        }, 
        "brief_title": "Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This will be a single-center, open label, 2-part study. Part 1 will be a two-period,\n      fixed-sequence crossover study with lenalidomide alone in Period 1, followed by lenalidomide\n      in combination with quinidine in Period 2. Part 2 will be a fixed-sequence, three-period,\n      crossover study with lenalidomide alone in Period 1, temsirolimus (via direct intravenous\n      infusion)  in Period 2, and lenalidomide in combination with temsirolimus (via direct\n      intravenous infusion) in Period 3.  Diphenhydramine (given via intravenous injection) will\n      be administered shortly before temsirolimus in order to decrease the chances of an allergic\n      reaction to temsirolimus.  Part 1 and Part 2 will be conducted at the same time.  Subjects\n      can only participate in either Part 1 or Part 2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must understand and voluntarily sign a written informed consent form prior to any\n             study-related procedures being performed.\n\n          -  Must be able to communicate with the investigator, understand and comply with the\n             requirements of the study, and agree to adhere to restrictions and examination\n             schedules.\n\n          -  Healthy male volunteer of any race between 18 to 65 years of age (inclusive), and in\n             good health as determined by a physical exam.\n\n          -  Agree to use barrier contraception (i.e., condoms not made of natural (animal)\n             membrane [e.g., latex or polyurethane condoms are acceptable]) when engaging in\n             sexual activity with a female of child-bearing potential while on study drug, and for\n             at least 90 days after the last dose of study drug.\n\n          -  Must have a body mass index between 18 and 33 kg/m2 (inclusive).\n\n          -  Clinical laboratory tests must be within normal limits or acceptable to the principal\n             investigator.\n\n          -  Must have confirmation of normal renal function (defined as an estimate glomerular\n             filtration rate >90 mL/min).\n\n          -  Must be afebrile, with supine systolic blood pressure: 90 to 140 mmHg, supine\n             diastolic blood pressure: 60 to 90 mmHg, and pulse rate: 40 to 110 bpm.\n\n          -  Must have a normal or clinically acceptable 12-lead electrocardiogram, with a QTcF\n             (Fridericia's correction formula) value \u2264 430 msec.\n\n          -  Must refrain from sperm donations for the entire duration of the study, and for at\n             least 90 days after the last dose of study drug.\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant and relevant neurological, gastrointestinal,\n             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,\n             hematological, allergic disease, drug allergies, known hypersensitivity to a member\n             of the class of immunomodulatory drugs (IMiDs\u00ae), temosirolimus, sirolimus,\n             polysorbate 80, diphenhydramine, or to any other component (or excipients) of\n             Torisel\u00ae, or other major disorders.\n\n          -  Any condition which places the subject at unacceptable risk if he were to participate\n             in the study, or confounds the ability to interpret data from the study.\n\n          -  Used any prescribed systemic or topical medication within 30 days of the first dose\n             administration, unless Sponsor agreement is obtained.\n\n          -  Used any non-prescribed systemic or topical medication (including vitamin/mineral\n             supplements, and herbal medicines) within 14 days of the first dose administration,\n             unless Sponsor agreement is obtained.\n\n          -  Used any prescribed, or non-prescribed, systemic or topical medication that is a\n             CYP3A inhibitor or inducer within 30 days of first dose administration.  (refer to\n             (http://medicine.iupui.edu/clinpharm/ddis/p450_Table_Oct_11_2009.pdf)\n\n          -  Has any surgical or medical conditions (excluding appendectomy) possibly affecting\n             drug absorption, distribution, metabolism and excretion, e.g., bariatric procedure.\n\n          -  Donated blood or plasma within 8 weeks before the first dose administration to a\n             blood bank or blood donation center.\n\n          -  History of drug abuse (as defined by the current version of the Diagnostic and\n             Statistical Manual within 2 years before dosing, or positive drug screening test\n             reflecting consumption of illicit drugs.\n\n          -  History of alcohol abuse (as defined by the current version of the Diagnostic and\n             Statistical Manual) within 2 years before dosing, or positive alcohol screen.\n\n          -  Known to have serum hepatitis or known to be a carrier of the hepatitis B surface\n             antigen (HBsAg), or hepatitis C antibody (HCVAb), or have a positive result to the\n             test for HIV antibodies at Screening.\n\n          -  Exposed to an investigational drug (new chemical entity) within 30 days preceding the\n             first dose administration, or 5 half-lives of that investigational drug, if known\n             (whichever is longer).\n\n          -  For Part 2 only: has total bilirubin \u2265 1.5x upper limit of normal"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712828", 
            "org_study_id": "CC-5013-CP-011"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lenalidomide plus Quinidine", 
                    "Lenalidomide plusTemsirolimus and Diphenhydramine"
                ], 
                "description": "25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lenalidomide plus Quinidine", 
                "description": "300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days", 
                "intervention_name": "Quinidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lenalidomide plusTemsirolimus and Diphenhydramine", 
                "description": "25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.", 
                "intervention_name": "Temsirolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lenalidomide plusTemsirolimus and Diphenhydramine", 
                "description": "Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.", 
                "intervention_name": "Diphenhydramine", 
                "intervention_type": "Drug", 
                "other_name": "Benadryl"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diphenhydramine", 
                "Promethazine", 
                "Quinidine", 
                "Krestin", 
                "Sirolimus", 
                "Everolimus", 
                "Thalidomide", 
                "Quinidine gluconate", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Lenalidomide,", 
            "Revlimid,", 
            "pharmacokinetics,", 
            "healthy male subjects"
        ], 
        "lastchanged_date": "February 12, 2013", 
        "link": {
            "url": "http://us.testwiththebest.com/find-our--clinics/our-dallas-clinic.html"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance Clinical Research Unit Dallas"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Edward O'Mara, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration-time curve from time zero to 24 hours post dose", 
                "measure": "Lenalidomide PK-AUC (0-24)", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 days"
            }, 
            {
                "description": "Maximum observed plasma concentration", 
                "measure": "Lenalidomide PK-(Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 days (including washout phase)"
            }, 
            {
                "description": "Time to maximum observed plasma concentration", 
                "measure": "Lenalidomide PK-(Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 days"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point", 
                "measure": "Lenalidomide PK-AUC(0-t)", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 days"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero extrapolated to infinity", 
                "measure": "Lenalidomide PK-AUC(0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 days"
            }, 
            {
                "description": "Estimate of the terminal elimination half-life in plasma", 
                "measure": "Lenalidomide PK-(T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 days"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to 24 hours post dose", 
                "measure": "Temsirolimus and Sirolimus PK-AUC (0-24)", 
                "safety_issue": "No", 
                "time_frame": "Up to 38 days"
            }, 
            {
                "description": "Maximum observed plasma concentration", 
                "measure": "Temsirolimus and Sirolimus PK-(Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 38 days"
            }, 
            {
                "description": "Time to maximum observed plasma concentration", 
                "measure": "Temsirolimus and Sirolimus PK-(Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 38 days"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point", 
                "measure": "Temsirolimus and Sirolimus PK-(AUC 0-t)", 
                "safety_issue": "No", 
                "time_frame": "Up to 38 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety monitoring will be done by regular adverse event assessment, concomitant medication, clinical laboratory tests, physical exams, ECGs, and vital signs.", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 weeks"
        }, 
        "source": "Celgene Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Covance", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}